Kodiak reported Q4 results yesterday”Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company’s differentiated molecules, platform and long term growth strategy,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences (KOD).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences rises 10.7%
- 3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
- Reiterating Buy on Kodiak: GLOW2 Validates Zenkuda’s Durable Efficacy and Multi‑Indication Path to Accelerated BLA
- Kodiak Sciences options imply 7.3% move in share price post-earnings
- Kodiak Sciences price target raised to $80 from $50 at UBS